CancerVax Therapeutic Melanoma Vaccine Launch Expected In 2006 – IPO
Executive Summary
CancerVax expects to launch its therapeutic melanoma vaccine and lead product candidate Canvaxin by 2006
You may also be interested in...
Pharmion IPO To Fund Vidaza Accelerated Approval For Bone Marrow Disorder
Pharmion will use proceeds from its initial public offering to file an accelerated approval NDA for its bone marrow disorder agent Vidaza (azacitidine) and begin a confirmatory Phase IV clinical trial
Pharmion IPO To Fund Vidaza Accelerated Approval For Bone Marrow Disorder
Pharmion will use proceeds from its initial public offering to file an accelerated approval NDA for its bone marrow disorder agent Vidaza (azacitidine) and begin a confirmatory Phase IV clinical trial
Genitope IPO Would Fund Phase III Cancer Vaccine Trials
Genitope plans to use proceeds from an initial public offering to fund enrollment of 360 patients in a pivotal study of the MyVax therapeutic cancer vaccine